Multiple Myeloma — An Interview with Dr Surbhi Sidana on Optimizing the Role of CAR T-Cell Therapy
Research To Practice | Oncology Videos · Dr. Neil Love
February 19, 202546m 31s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Featuring an interview with Dr Surbhi Sidana, including the following topics:
- Long-term outcomes for patients with relapsed/refractory multiple myeloma (MM) (0:00)
- Clinical considerations in the selection of patients for chimeric antigen receptor (CAR) T-cell therapy (3:34)
- Practical challenges for patients receiving CAR T-cell therapy (8:34)
- Selection among available CAR T-cell therapies (12:18)
- Prevention, management and supportive care involved in the management of toxicities associated with CAR T-cell therapy (16:34)
- Secondary cancers associated with CAR T-cell therapy (21:25)
- Bridging therapy considerations for patients receiving CAR T-cell treatment (25:15)
- Utility of antibody-drug conjugates and bispecific antibodies for MM (27:49)
- Case: A man in his early 40s experiences rapid progression on induction therapy for MM (31:59)
- Case: A man in his early 50s with heavily pretreated MM receives multiple CAR T-cell therapies (41:47)